Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | MPO | P05164 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23225646 | 0.80 | OPRM1 (0.45) | OPRM1MPOLMNAPOLBTSHR | |
| SCHEMBL23225647 | 0.79 | OPRM1 (0.46) | OPRM1MPOBCHELMNAPOLB | |
| SCHEMBL23225605 | 0.77 | OPRM1 (0.44) | OPRM1MPOBCHELMNAPOLB | |
| SCHEMBL23217973 | 0.76 | OPRM1 (0.43) | OPRM1MPOLMNAPOLBTSHR | |
| SCHEMBL23225723 | 0.75 | OPRM1 (0.45) | OPRM1MPOLMNAPOLBTSHR | |
| SCHEMBL23217980 | 0.74 | OPRM1 (0.33) | OPRM1MPO | |
| Verdiperstat SCHEMBL23225670 | 0.74 | MPO (0.58) | OPRM1MPO | |
| SCHEMBL23217941 | 0.73 | OPRM1 (0.40) | OPRM1MPOLMNAPOLBTSHR | |
| SCHEMBL23217928 | 0.72 | OPRM1 (0.47) | OPRM1MPOLMNATSHRHSP90AA1 | |
| SCHEMBL23217978 | 0.71 | OPRM1 (0.33) | OPRM1MPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067651-A1 | PRODRUGS OF MYELOPEROXIDASE INHIBITORS | BIOHAVEN THERAPEUTICS LTD. | 2024-02-29 | — | — | US | disclosed |
| US-20240067651-A1 | PRODRUGS OF MYELOPEROXIDASE INHIBITORS | BIOHAVEN THERAPEUTICS LTD. | 2024-02-29 | — | — | US | disclosed |
| EP-4041735-A1 | PRODRUGS OF MYELOPEROXIDASE INHIBITORS | Biohaven Therapeutics Ltd. (US) | 2022-08-17 | — | — | EP | disclosed |
| WO-2021072140-A1 | PRODRUGS OF MYELOPEROXIDASE INHIBITORS | BIOHAVEN THERAPEUTICS LTD. (US) | 2021-04-15 | — | — | WO | disclosed |
| WO-2021072140-A1 | PRODRUGS OF MYELOPEROXIDASE INHIBITORS | BIOHAVEN THERAPEUTICS LTD. (US) | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067651-A1 | PRODRUGS OF MYELOPEROXIDASE INHIBITORS | MPO, CAT, SOD1 | OPRM1 1161/4885MPO 1/4885BCHE 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.